In a patient with recent alcohol intake and a CIWA‑Ar (Clinical Institute Withdrawal Assessment for Alcohol, revised) score of 10, can propofol be administered together with midazolam boluses?

Propofol with Midazolam for CIWA 10 in Recent Alcohol Use: Not Recommended

Do not combine propofol with midazolam boluses for managing a CIWA-Ar score of 10 in a patient with recent alcohol intake. Benzodiazepines alone are the gold standard for alcohol withdrawal syndrome, and adding propofol introduces unnecessary respiratory and hemodynamic risks without established benefit in this specific clinical context.

Rationale for Benzodiazepines as Monotherapy

Benzodiazepines are the established first-line treatment for moderate alcohol withdrawal syndrome (CIWA-Ar >8). 1 A CIWA-Ar score of 10 indicates moderate AWS requiring pharmacological intervention, but this severity does not justify the use of propofol, which is reserved for refractory cases or deep sedation requirements. 1

• Midazolam alone is appropriate for this patient. For moderate AWS (CIWA-Ar 10), start with midazolam 2 mg IV boluses every 5 minutes as needed, titrating to symptom control. 2 The FDA-approved dosing for sedation in adults under 60 years is up to 2.5 mg over at least 2 minutes, with additional 2-minute intervals between doses to assess effect. 3

• Symptom-triggered regimens are preferred over fixed-dose schedules to prevent benzodiazepine accumulation, particularly important given this patient's recent alcohol intake and potential for ongoing intoxication effects. 1

Why Propofol Should Not Be Added

Propofol has no role in routine alcohol withdrawal management and significantly increases risk without evidence of benefit. The combination of propofol with midazolam creates several critical safety concerns:

• Synergistic respiratory depression: Propofol combined with midazolam produces deeper sedation than either agent alone, with documented increased risk of respiratory depression, airway obstruction, and hypoxemia. 4 One study specifically noted that combining propofol with midazolam resulted in deeper sedation levels and more episodes of deep sedation compared to propofol alone. 4

• Hemodynamic instability: Propofol causes dose-dependent hypotension and can precipitate bradycardia. 5 In a patient with recent alcohol intake who may have volume depletion or autonomic instability from early withdrawal, this risk is amplified. Post-cardiac surgery studies showed significant decreases in blood pressure with propofol. 6

• No analgesic properties: Propofol provides no analgesia and has no specific anti-withdrawal effects beyond sedation. 5 It does not address the underlying GABA/NMDA receptor dysregulation that drives alcohol withdrawal. 7

• Risk of propofol infusion syndrome: While typically associated with prolonged high-dose infusions, propofol carries risks of hypertriglyceridemia, pancreatitis, and metabolic acidosis. 5

When Propofol Might Be Considered (Not This Case)

Propofol is only appropriate as a second-line agent for refractory alcohol withdrawal when benzodiazepines have failed to control severe symptoms:

• Severe, benzodiazepine-refractory AWS: When patients require deep sedation despite escalating benzodiazepine doses, propofol or barbiturates may be used as rescue therapy. 8 This typically occurs in ICU settings with CIWA-Ar scores consistently >15-20 despite aggressive benzodiazepine therapy.

• Intubated patients requiring deep sedation: In mechanically ventilated patients with delirium tremens, propofol can be used as an alternative to benzodiazepines for sedation. 8 However, this patient with CIWA-Ar 10 does not meet criteria for intubation.

• Propofol as alternative, not additive: Guidelines suggest propofol as an alternative to benzodiazepines in specific contexts, not as a combination therapy. 8

Correct Management Algorithm for CIWA-Ar 10

Step 1: Assess and stabilize

• Evaluate for concurrent conditions: hypoglycemia (give thiamine 100 mg IV before dextrose), electrolyte abnormalities (particularly hypomagnesemia, hypokalemia), trauma, infection. 7
• Establish IV access and continuous monitoring (pulse oximetry, cardiac monitoring, blood pressure). 3

Step 2: Initiate benzodiazepine therapy

• Midazolam 2-2.5 mg IV bolus over at least 2 minutes. 3 Wait an additional 2 minutes to assess effect before redosing. 3
• Repeat every 5 minutes as needed until CIWA-Ar <8 or patient shows adequate sedation (calm, drowsy but arousable). 2
• For patients >60 years or with COPD/hepatic dysfunction, reduce initial dose to 1-1.5 mg. 3

Step 3: Consider continuous infusion if boluses insufficient

• If patient requires ≥2 boluses within an hour, initiate midazolam infusion at 1 mg/hr and continue boluses as needed. 8
• Titrate infusion upward if breakthrough symptoms occur. 8

Step 4: Escalate only if benzodiazepines fail

• If CIWA-Ar remains >15 despite aggressive benzodiazepine therapy (>20 mg midazolam in first hour), consider phenobarbital or ICU transfer for potential propofol/intubation. 7

Critical Pitfalls to Avoid

• Do not use propofol outside ICU settings for alcohol withdrawal. It requires continuous monitoring and immediate airway management capability. 3

• Do not combine sedatives prematurely. The synergistic effect of midazolam plus propofol can cause rapid progression from moderate to deep sedation with loss of protective airway reflexes. 4, 3

• Avoid rapid IV administration. Both midazolam and propofol require slow titration; rapid injection increases risk of respiratory depression and hypotension. 3

• Recent alcohol intake increases risk. Active alcohol in the system combined with CNS depressants (midazolam ± propofol) creates additive respiratory depression. 3 The patient should be monitored for signs of concurrent intoxication.

• CIWA-Ar 10 does not indicate severe withdrawal. Scores ≥15 indicate severe AWS; a score of 10 is moderate and should respond to benzodiazepines alone. 1, 9